ASX healthcare stocks shrug off new tariff threat
Stocks
ASX healthcare stocks shrug off new tariff threat
Trump’s announcement could directly affect CSL, but we expect the firm to respond accordingly.
Undervalued ASX biotech
Stocks
Undervalued ASX biotech
Despite improving prospects the shares continue to sell off.
Market too optimistic on new contract for ASX highflyer
Stocks
Market too optimistic on new contract for ASX highflyer
Notable contract win, but market is limited.
ASX healthcare leader undervalued after share slump
Stocks
ASX healthcare leader undervalued after share slump
The sell-off in this moated healthcare company ignores strong potential for revenue growth and margin improvement.
Expensive ASX star looks vulnerable to slowing sales growth
Stocks
Expensive ASX star looks vulnerable to slowing sales growth
Cochlear’s biggest market segment has matured and it is looking elsewhere for growth.
Overvalued ASX pharma play hits FDA speedbump
Stocks
Overvalued ASX pharma play hits FDA speedbump
We think a delay rather than an outright rejection for this company’s product is the likelier outcome, but the shares still look expensive.
ASX healthcare leader continues to prove the doubters wrong
Stocks
ASX healthcare leader continues to prove the doubters wrong
Niche play with more growth potential than many investors give it credit for.
Undervalued ASX share announces plan to create shareholder value
Stocks
Undervalued ASX share announces plan to create shareholder value
The market cheers update from the company.
Undervalued ASX listed share with strong growth prospects
Stocks
Undervalued ASX listed share with strong growth prospects
The company is poised to take advantage of clear overarching macro revenue drivers.
Ask the analyst: Are IDP Education's woes temporary?
Stocks
Ask the analyst: Are IDP Education's woes temporary?
The global education services provider has gone from stock market darling to one of the ASX's weakest performers. What gives?
of 5
Viewing 1 to 10 of 47